Literature DB >> 8230625

Continuous intrathecal baclofen infusion for spasticity of cerebral origin.

A L Albright1, W B Barron, M P Fasick, P Polinko, J Janosky.   

Abstract

OBJECTIVE: To determine if continuous intrathecal baclofen infusion (CIBI) would provide continuous relief of spasticity in patients with spasticity of cerebral origin, especially children with cerebral palsy.
DESIGN: Prospective, unblinded trial, before and after CIBI.
SETTING: Children's Hospital of Pittsburgh (Pa). PATIENTS: Thirty-seven patients, 5 to 27 years of age, with spasticity of cerebral origin. INTERVENTION: Continuous intrathecal baclofen infusion for 3 to 48 months. MAIN OUTCOME MEASURES: Muscle tone, range of motion, upper extremity timed tasks, activities of daily living (ADLs).
RESULTS: Six and 12 months after CIBI, muscle tone was significantly decreased in the upper (P = .04) and lower (P = .001) extremities. There was a significant relationship between baclofen dosage and muscle tone in the upper (P = .02) and lower (P = .001) extremities. Hamstring motion, upper extremity function, and ADLs were significantly improved in 25 patients who were capable of self-care.
CONCLUSION: Spasticity of cerebral origin can be effectively treated with CIBI. Because baclofen dosages can be titrated for the desired clinical response, CIBI is particularly useful for patients who need some spasticity to stand and ambulate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230625

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  34 in total

1.  Virtual electric power wheelchair driving performance of individuals with spastic cerebral palsy.

Authors:  Brad E Dicianno; Harshal Mahajan; Alcinto S Guirand; Rory A Cooper
Journal:  Am J Phys Med Rehabil       Date:  2012-10       Impact factor: 2.159

2.  Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity.

Authors:  Casey Melissa Berman; Melissa Ann Eppinger; Catherine Anne Mazzola
Journal:  Childs Nerv Syst       Date:  2014-11-16       Impact factor: 1.475

3.  Absent virtues: the poacher becomes gamekeeper.

Authors:  T Koch
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

4.  Long-term intrathecal baclofen therapy in ambulatory patients with spasticity.

Authors:  Saud A Sadiq; Gary C Wang
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

Review 5.  Intrathecal baclofen for childhood hypertonia.

Authors:  A Leland Albright
Journal:  Childs Nerv Syst       Date:  2007-06-29       Impact factor: 1.475

6.  New approaches to managing spasticity in children with cerebral palsy.

Authors:  D Im; C M McDonald
Journal:  West J Med       Date:  1997-04

7.  European Society for Stereotactic and Functional Neurosurgery. Milan, Italy, June 12-15, 1996. Abstracts.

Authors: 
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 8.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

Review 9.  Treatment of stroke in older patients. A state of the art review.

Authors:  G Harper
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

10.  Influence of baclofen on laryngeal and spinal motor drive during cough in the anesthetized cat.

Authors:  Daniel Castillo; Teresa Pitts
Journal:  Laryngoscope       Date:  2013-05-13       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.